

Cleansing Notice

For Immediate Release: March 9, 2016

Sydney, Australia – Simavita Limited (ASX: SVA; TSX-V: SV) ("Simavita" or the "Company") refers to the Appendix 3B released on March 3, 2016 for the issue of 6,666,667 CHESS Depositary Interests (**CDIs**).

The Company notifies the ASX under section 708A(5)(e) of the Corporations Act (the Act) that:

- the Company issued the CDIs without disclosure to the investors under Part 6D.2 of the Act;
- 2. as at March 3, 2016, the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company, and section 674 of the Act; and
- 3. as at March 3, 2016, there is no information:
 - a. that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
 - b. that investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
 - i. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
 - ii. the rights and liabilities attaching to the CDIs.

For further information, see our website (www.simavita.com) or contact the persons outlined below.

Company	Media and Investor Relations
Philippa Lewis, Chief Executive Officer T: +61 2 8405 6381	Glen Zurcher E: glen.zurcher@irdepartment.com.au T: +61 420 249 299

About Simavita

Simavita is a digital healthcare company that has developed an innovative software platform. The first application for the platform is a world first solution for the management of urinary incontinence, with a focus on the elderly. This platform technology is an instrumented incontinence assessment application that provides evidence-based incontinence management care plans to the residential aged care market.

About SIM®

SIM® is a wireless sensor technology that delivers evidence-based instrument incontinence data on individuals. SIM® provides user friendly tools and software to assess the incontinence condition and to help plan better outcomes. SIM® is used to detect, record and report incontinence events during a compulsory or recommended assessment period in residential aged care facilities to develop an evidence-based incontinence care plan.

Conducting assessments is mandatory in many countries and the incontinence assessment creates an influential element of care of each individual. For more information on Simavita or SIM®, please visit www.simavita.com.

The TSX Venture Exchange has in no way passed upon the merits of the transactions set out herein and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange not its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this Release.